FindMyKOL

Robert Haddad, MD

Enriched profile

Chief, Division of Head and Neck Oncology · Dana-Farber Cancer Institute

ORCIDNone on fileNPI↗
✓ Itemized profile
Region🇺🇸 Boston, MA · Northeast · United StatesSpecialtyMedical OncologyFocusHead & Neck Cancer+4
Active KOLFindMyKOL type: NationalLatest publicationNone indexedOnline presenceverified 2026Payments2021–2025NIH funding2019–2019Why? →

Robert Haddad is Chief, Division of Head and Neck Oncology at Dana-Farber Cancer Institute. ClinicalTrials.gov lists 15 registered studies with this person as an investigator.

Data verified 13 Nov 2026

Overview

Updated 17 Nov 2026

Robert Haddad, MD, is Chief, Division of Head and Neck Oncology at Dana-Farber Cancer Institute. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 25 companies, 1 NIH-funded awards (2019–2019).

  • Top research focus: Head & Neck Cancer
  • 15 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 25 companies

Generated from the cited public record · current as of 17 Nov 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Head & Neck Cancer12 trialsCarcinoma, Squamous Cell6 trialsCarcinoma, Merkel Cell2 trialsCarcinoma, Adenoid Cystic1 trialCysts1 trialHypopharyngeal Neoplasms1 trialMelanoma1 trialMucositis1 trialNasopharyngeal Neoplasms1 trialPapilloma1 trialPharyngeal Neoplasms1 trialSalivary Gland Neoplasms1 trialSkin Neoplasms1 trialXerostomia1 trial

Research focus

OpenAlex concept fingerprint
Head & Neck CancerCarcinoma, Squamous CellCarcinoma, Merkel CellPapillomaSkin Neoplasms

Drugs & molecules

across trials, industry payments and publications
Keytrudageneric · PembrolizumabClinical trials—Industry payments75Publications—Lenvimageneric · LenvatinibClinical trials—Industry payments18Publications—Vitrakvigeneric · LarotrectinibClinical trials—Industry payments9Publications—Fotivdageneric · TivozanibClinical trials—Industry payments4Publications—Tivdakgeneric · TisotumabClinical trials—Industry payments2Publications—Udenycageneric · PegfilgrastimClinical trials—Industry payments2Publications—Coselageneric · TrilaciclibClinical trials—Industry payments1Publications—Rybrevantgeneric · AmivantamabClinical trials—Industry payments1Publications—Tevimbrageneric · TislelizumabClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Merck Sharp & Dohme LLCClinical trials—Industry payments107Boehringer Ingelheim International GmbHClinical trials—Industry payments14Dana-Farber Cancer InstituteClinical trials10Industry payments—Eisai Inc.Clinical trials—Industry payments10Hikma Pharmaceuticals USAClinical trials—Industry payments10Bayer HealthCare Pharmaceuticals Inc.Clinical trials—Industry payments9GlaxoSmithKline, LLC.Clinical trials—Industry payments9EMD Serono, Inc.Clinical trials—Industry payments7Exelixis Inc.Clinical trials—Industry payments7Coherus Biosciences Inc.Clinical trials—Industry payments6Aveo Pharmaceuticals, Inc.Clinical trials—Industry payments5AstraZeneca UK LimitedClinical trials—Industry payments4Genmab U.S., Inc.Clinical trials—Industry payments4Merck Sharp & Dohme CorporationClinical trials—Industry payments4AstraZeneca Pharmaceuticals LPClinical trials—Industry payments3E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments3Merck KGaAClinical trials—Industry payments3Abbvie Inc.Clinical trials—Industry payments2Janssen Research & Development, LLCClinical trials—Industry payments2Janssen Scientific Affairs, LLCClinical trials—Industry payments2Ascendis Pharma IncClinical trials—Industry payments1AstraZenecaClinical trials1Industry payments—BeiGene USA, Inc.Clinical trials—Industry payments1Foundation for the National Institutes of HealthClinical trials1Industry payments—G1 Therapeutics, Inc.Clinical trials—Industry payments1IO BiotechClinical trials1Industry payments—Janssen Pharmaceuticals, IncClinical trials—Industry payments1Robert Haddad, MDClinical trials1Industry payments—Tempus AIClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓

Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →

Clinical & industry

trials, payments and federal funding
15clinical trials

Investigator role on registered studies.

View trials ↓
25companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 2019–2019

Federally funded research awards.

View funding ↓

Industry payments

Updated 13 Nov 2026

25 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    100%
    Antiarrhythmic100%
    Lidocaine Hcl Viscous100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 13 Nov 2026

1 NIH research award on record, funded 2019–2019 per NIH RePORTER. The latest:

Publications

None on file yet. We only list publications we can confidently match to this person. Why? →

Online presence

Updated 13 Nov 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/robert-haddad-md-bc5537b3

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗

Mentions by others

where others cite or feature them
  • Other

    dana-farber.org/find-a-doctor/robert-i-haddad

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • Other

    hcc.harvard.edu/members/dr-robert-haddad

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hcc.harvard.edu ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 13 Nov 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD Degree

    St. Joseph University French School of Medicine in Beirut

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗

Editorial & leadership roles

journal and society appointments
  • Member

    American Society of Clinical Oncology

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hcc.harvard.edu ↗
  • Member

    American Association for Cancer Research

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hcc.harvard.edu ↗
  • Member

    European Society of Medical Oncology

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hcc.harvard.edu ↗
  • Member

    American Society for Therapeutic Radiology and Oncology

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hcc.harvard.edu ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.